nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Abstracts
|
|
|
2004 |
|
4 |
p. 1-28 28 p. |
artikel |
2 |
ADMA and oxidative stress
|
Sydow, Karsten |
|
2003 |
|
4 |
p. 41-51 11 p. |
artikel |
3 |
ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease
|
Böger, Rainer H. |
|
2003 |
|
4 |
p. 23-28 6 p. |
artikel |
4 |
A new reality: achieving cholesterol-lowering goals in clinical practice
|
Gaw, Allan |
|
2002 |
|
4 |
p. 5-11 7 p. |
artikel |
5 |
A scientific rationale for the CREST trial results: Evidence for the mechanism of action of cilostazol in restenosis
|
Morishita, Ryuichi |
|
2005 |
|
4 |
p. 41-46 6 p. |
artikel |
6 |
Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events
|
Valkonen, Veli-Pekka |
|
2003 |
|
4 |
p. 19-22 4 p. |
artikel |
7 |
Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase
|
Böger, Rainer H. |
|
2003 |
|
4 |
p. 1-3 3 p. |
artikel |
8 |
ATP-binding cassette A1 protein and HDL homeostasis
|
Owen, James S |
|
2002 |
|
4 |
p. 13-22 10 p. |
artikel |
9 |
Cilostazol in secondary prevention of stroke: Impact of the Cilostazol Stroke Prevention Study
|
Matsumoto, Masayasu |
|
2005 |
|
4 |
p. 33-40 8 p. |
artikel |
10 |
Cilostazol: Potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding
|
Goto, Shinya |
|
2005 |
|
4 |
p. 3-11 9 p. |
artikel |
11 |
Corrigendum to “Trans-fatty acids and sudden cardiac death” [Atheroscler. Suppl. 7 (2006) 13–15]
|
Lemaitre, Rozenn N. |
|
2006 |
|
4 |
p. 33- 1 p. |
artikel |
12 |
Editorial Board
|
|
|
2005 |
|
4 |
p. iii- 1 p. |
artikel |
13 |
Effect on platelet function of cilostazol, clopidogrel, and aspirin, each alone or in combination
|
Comerota, Anthony J. |
|
2005 |
|
4 |
p. 13-19 7 p. |
artikel |
14 |
Evidence-based goals versus achievement in clinical practice in secondary prevention of coronary heart disease: findings in EUROASPIRE II
|
De Backer, Guy |
|
2002 |
|
4 |
p. 13-17 5 p. |
artikel |
15 |
HDL in risk prediction and its direct and indirect involvement in atherogenesis
|
Durrington, Paul |
|
2002 |
|
4 |
p. 3-12 10 p. |
artikel |
16 |
HDL therapy for the acute treatment of atherosclerosis
|
Newton, Roger S |
|
2002 |
|
4 |
p. 31-38 8 p. |
artikel |
17 |
Healthy food and healthy choices: A new European profile approach
|
|
|
2009 |
|
4 |
p. 1-11 11 p. |
artikel |
18 |
High risk/high priority: familial hypercholesterolemia — a paradigm for molecular medicine
|
Schuster, Herbert |
|
2002 |
|
4 |
p. 27-32 6 p. |
artikel |
19 |
Hugh Sinclair Lecture: The regulation and remodelling of HDL by plasma factors
|
Barter, P.J |
|
2002 |
|
4 |
p. 39-47 9 p. |
artikel |
20 |
Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA
|
Lentz, Steven R. |
|
2003 |
|
4 |
p. 61-65 5 p. |
artikel |
21 |
Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase
|
Tselepis, Alexandros D |
|
2002 |
|
4 |
p. 57-68 12 p. |
artikel |
22 |
Introduction
|
Durrington, Paul |
|
2002 |
|
4 |
p. 1- 1 p. |
artikel |
23 |
Introduction
|
Chait, Alan |
|
2006 |
|
4 |
p. 1-4 4 p. |
artikel |
24 |
Introduction
|
Hiatt, W.R. |
|
2005 |
|
4 |
p. 1- 1 p. |
artikel |
25 |
Is insulin resistance atherogenic? A review of the evidence
|
Ferrannini, Ele |
|
2006 |
|
4 |
p. 5-10 6 p. |
artikel |
26 |
Is insulin resistance atherogenic? Possible mechanisms
|
DeFronzo, Ralph A. |
|
2006 |
|
4 |
p. 11-15 5 p. |
artikel |
27 |
Lectures in the 3rd Baltic Atherosclerosis Congress Supplement
|
|
|
2004 |
|
4 |
p. 29-41 13 p. |
artikel |
28 |
Lipid-lowering — translating evidence into benefits
|
Shepherd, James |
|
2002 |
|
4 |
p. 1-3 3 p. |
artikel |
29 |
Managing diabetic dyslipidaemia—beyond LDL-C:HDL-C and triglycerides
|
Barter, Philip |
|
2006 |
|
4 |
p. 17-21 5 p. |
artikel |
30 |
NO and angiogenesis
|
Cooke, John P. |
|
2003 |
|
4 |
p. 53-60 8 p. |
artikel |
31 |
Old and new cardiovascular risk factors: from unresolved issues to new opportunities
|
Maas, Renke |
|
2003 |
|
4 |
p. 5-17 13 p. |
artikel |
32 |
Optimizing the pharmacology of statins: characteristics of rosuvastatin
|
Chapman, M.John |
|
2002 |
|
4 |
p. 33-37 5 p. |
artikel |
33 |
Paraoxonase and coronary heart disease
|
Mackness, Michael I |
|
2002 |
|
4 |
p. 49-55 7 p. |
artikel |
34 |
Plasma concentration of asymmetric dimethylarginine and the risk of coronary heart disease: rationale and design of the multicenter CARDIAC study
|
Mügge, Andreas |
|
2003 |
|
4 |
p. 29-32 4 p. |
artikel |
35 |
Preface
|
|
|
2004 |
|
4 |
p. x- 1 p. |
artikel |
36 |
Reverse cholesterol transport in man: promotion of fecal steroid excretion by infusion of reconstituted HDL
|
Angelin, Bo |
|
2002 |
|
4 |
p. 23-30 8 p. |
artikel |
37 |
Role of adjunct pharmacologic therapy in the era of drug-eluting stents
|
Douglas Jr., John S. |
|
2005 |
|
4 |
p. 47-52 6 p. |
artikel |
38 |
The apolipoprotein story
|
Sacks, Frank M. |
|
2006 |
|
4 |
p. 23-27 5 p. |
artikel |
39 |
The DDAH/ADMA/NOS pathway
|
Tran, Cam T.L |
|
2003 |
|
4 |
p. 33-40 8 p. |
artikel |
40 |
The lower the better? Reviewing the evidence for more aggressive cholesterol reduction and goal attainment
|
Stein, Evan |
|
2002 |
|
4 |
p. 19-25 7 p. |
artikel |
41 |
The US experience with cilostazol in treating intermittent claudication
|
Hiatt, William R. |
|
2005 |
|
4 |
p. 21-31 11 p. |
artikel |
42 |
Type-2 diabetes mellitus related cardiovascular risk: New options for interventions to reduce risk and treatment goals
|
Hobbs, F.D. Richard |
|
2006 |
|
4 |
p. 29-32 4 p. |
artikel |